David joined Seagen as Chief Executive Officer and a member of the Board of Directors in 2022, bringing more than 30 years of drug development, deal making, commercialization and people leadership experience on a global scale. During his tenure, Seagen’s portfolio of innovative cancer medicines has grown significantly, and he prioritized its research and development focus and plans for continued growth, including an expanded presence globally.
Prior to Seagen, David was executive partner at Flagship Pioneering, a developer of bioplatform companies. From early-2010 to mid-2016, he served as chief executive officer of Novartis Pharmaceuticals, a division of Novartis AG. Previously, David started and led Novartis’ Oncology and Molecular Diagnostic units. Under his leadership the company’s oncology business grew to the second largest in the world. He’s led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Glivec, Tasigna, Gilenya, Afinitor, Cosentyx and Entresto. He was also recognized by FierceBiotech as one of the “25 most influential people in biopharma.”
David holds a B.S. Degree in Pharmacy from Rutgers University College of Pharmacy (1984) and an MBA in Finance and Marketing from the Columbia University Graduate School of Business (1987). He serves as a board member at Valo Health, a company using technology to reimagine drug discovery and development, and Opy Acquisition Corp, a life sciences investment company.